Regulus

Type: Keyphrase
Name: Regulus
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

US Federal Business Opportunity: Other Defense Agencies: Instrumented Cylinder Head Test Equipment

Agency: Other Defense AgenciesOffice: U.S. Special Operations Command Location: Naval Special Warfare Development GroupDate you need to respond by: 7-July-2014Solicitation Number: H92244-14-T-0264 Naics code: 334519 Computer and Electronic Product M ... [Published ITbriefing - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Regulus Gains Orphan Drug Designation for microRNA Treatment

A recent press release  by the company Regulus Therapeutics highlights their newest orphan drug RG-012 – a microRNA treatment designed to help patients with Alport Syndrome, a life-threatening genetic kidney disease that impacts the body’s ability to ... [Published Terrapinn - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Regulus Receives FDA Orphan Status For Rare Kidney Disease Drug

By Estel Grace MasangkayBiopharmaceutical company Regulus Therapeutics announced that the U.S. Food and Drug Administration (FDA) have issued Orphan Drug designation to its RG-012 for the treatment of rare kidney disease Alport syndrome.RG-012 is being ... [Published Bioresearch Online - Jul 23 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 7 reports

Regulus gets FDA orphan drug status for RG-012 to treat Alport Syndrome

US-based biopharmaceutical firm Regulus Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for RG-012, a single stranded, chemically modified oligonucleotide. ... [Published PBR - News - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 2 reports

Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome

LA JOLLA, Calif."We are pleased to have received orphan drug designation for RG-012 and are encouraged by the FDA's recognition for the need of innovative new treatments like microRNA therapeutics for rare and orphan diseases such as Alport syndrome," ... [Published Bio-Medicine - Jul 21 2014]
First reported Jul 19 2014 - Updated Jul 19 2014 - 1 reports

US Federal Business Opportunity: Other Defense Agencies: AVAYA brand Phone Equipment/Install

Agency: Other Defense AgenciesOffice: U.S. Special Operations Command Location: Naval Special Warfare Development GroupDate you need to respond by: 19-July-2014Classification Code: 58 -- Communication, detection, & coherent radiation equipmentSolicitation ... [Published ITbriefing - Jul 19 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Orphan Drug status for Regulus kidney disease therapeutic candidate

11:19 ET | About: Regulus Therapeutics (RGLS)The FDA designates Regulus Therapeutics' (RGLS +3%) miR-21 inhibitor RG-012 an Orphan Drug for the treatment of Alport syndrome. miR-21 is a 22-mer non-coding RNA that is up-regulated in fibrotic kidney disease. ... [Published Seeking Alpha - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Thoma-Sea launches newbuild for GulfMark

| More Thoma-Sea Shipbuilders recently launched Regulus, a DP 2, FiFi I offshore supply vessel from its Houma shipyard.The 272ft OSV was built to service deep water oil and gas exploration. The vessel has two 2,000kW Z-drives and two 850kW bow thrusters ... [Published Offshore Shipping Online - Jul 18 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Berko: The skinny on convertible bonds

Dear Mr. Berko:Please tell me what a convertible bond is and why so few brokers recommend convertible bonds. I’d like to invest a portion of my portfolio in convertible bonds but don’t know where to find research on these strange securities. What do you ... [Published Des Moines Business Record - Jul 11 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 2 reports

General Public to Vote for Exoplanet Names

Naming something can be so much fun but this fun surely increases if someone is a part of the amateur astronomy group and can help bestow names on exoplanets. Also, 305 exoplanets have been opened by the International Astronomical Union for public to ... [Published French Tribune - Jul 10 2014]
Entities: Exoplanet, Arabic, Fomalhaut
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Black women artists present interactive performance

The Antioch College performance program will present Call & Response, a dynamic of black women and performance, on July 18-22 and August 23-24.Part symposium, part residency, part festival, Call & Response will feature six diverse black women artists ... [Published Dayton Daily News - Jul 08 2014]
First reported Jun 29 2014 - Updated Jun 29 2014 - 1 reports

Taking Stock: Brokers have reasons to avoid convertible bonds

Dear Mr. Berko: Please tell me what a convertible bond is and why so few brokers recommend convertible bonds. I’d like to invest a portion of my portfolio in convertible bonds but don’t know where to find research on these strange securities. What do ... [Published NewsOK.com - Jun 29 2014]

Quotes

...like microRNA therapeutics for rare and orphan diseases such as Alport syndrome," said Paul Grint, M D , Chief Medical Officer of Regulus.  "Alport syndrome is a life threatening disease and patients have very limited treatment options because there is currently no approved therapy.  We believe that RG-012 represents an opportunity to make a significant impact in the lives of patients with Alport syndrome and we look forward to advancing this program into the clinic." In the near term, Regulus expects to initiate a natural history of disease study to gather further information about the progression of Alport syndrome...
"Adjust Your Child Birth Date to August 18 - on Conjunction of Jupiter and Venus"
As if this risks were not enough, let us look at the footnote for CAP. The S-1 says: "The PPA counterparty has the right, under certain circumstances, to purchase up to 40% of the project equity from us pursuant to a predetermined purchase price formula. See "Business-Our Portfolio-Initial Portfolio-Utility Projects-CAP.""
...therapy similar to Microlin's antimicroRNA (AMT) candidate for lung cancer is being developed by Regulus and Sanofi ($SNY), according to the S-1. "In comparison, our antimiR-21 AMT drug candidate, Lumiralin, incorporates the proprietary delivery technology based on QTsome lipid nanoparticles and we believe is likely to be much more potent" the company says. Other advantages of QTsome cited include its ease of manufacture and fewer side effects due to a lower dosage requirement

More Content

All (105) | News (72) | Reports (0) | Blogs (31) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
Southern Cross Stargazer for July 27-Aug. 2, 2014 [Published Miami Herald - 13 hours ago]
US Federal Business Opportunity: Other Defense ... [Published ITbriefing - Jul 25 2014]
Regulus Gains Orphan Drug Designation for micro... [Published Terrapinn - Jul 24 2014]
Regulus Receives FDA Orphan Status For Rare Kid... [Published Bioresearch Online - Jul 23 2014]
Regulus gets FDA orphan drug status for RG-012 ... [Published PBR - News - Jul 22 2014]
Happy Birthday, Prince George! the Royal Baby T... [Published Yahoo! Shine - Jul 21 2014]
Regulus Receives FDA Orphan Drug Designation fo... [Published PharmaceuticalProcessing - Jul 21 2014]
Regulus Gets Orphan Drug Designation For RG-012... [Published RTTNews.com - Jul 21 2014]
Regulus Receives Orphan Drug Designation for RG... [Published Bio-Medicine - Jul 21 2014]
Regulus Therapeutics Inc receives orphan drug d... [Published Reuters - Jul 21 2014]
Regulus Therapeutics granted orphan drug design... [Published Yahoo! Finance - Jul 21 2014]
Regulus Receives Orphan Drug Designation for RG... [Published Wall Street Select - Jul 21 2014]
Regulus Receives Orphan Drug Designation for RG... [Published ADVFN India - Jul 21 2014]
Regulus Receives Orphan Drug Designation for RG... [Published PR Newswire: Policy & Public Interest - Jul 21 2014]
US Federal Business Opportunity: Department of ... [Published ITbriefing - Jul 19 2014]
US Federal Business Opportunity: Other Defense ... [Published ITbriefing - Jul 19 2014]
Orphan Drug status for Regulus kidney disease t... [Published Seeking Alpha - Jul 18 2014]
Thoma-Sea launches newbuild for GulfMark [Published Offshore Shipping Online - Jul 18 2014]
"Adjust Your Child Birth Date to August 18 - on... [Published SBWire - Jul 15 2014]
TerraForm Power S-1 Teardown: Is SunEdison Guil... [Published Seeking Alpha - Jul 15 2014]
Movers and Shakers July 2014 [Published PM 360 - Jul 11 2014]
US Federal Business Opportunity: Department of ... [Published ITbriefing - Jul 11 2014]
Berko: The skinny on convertible bonds [Published Des Moines Business Record - Jul 11 2014]
A Defense of Poetry - Percy Bysshe Shelly (Part... [Published Examiner.com - Jul 11 2014]
Seacem shares rise after takeover news [Published Manila Standard Today - Jul 10 2014]
Seacem gets nickel assets as shareholders sell out [Published Business World - Jul 10 2014]
General Public to Vote for Exoplanet Names [Published French Tribune - Jul 10 2014]
Fancy an exoplanet? Fill in this form and hope ... [Published The Register - Jul 10 2014]
Black women artists present interactive perform... [Published Dayton Daily News - Jul 08 2014]
US Federal Business Opportunity: Other Defense ... [Published ITbriefing - Jul 08 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Regulus gets FDA orphan drug status for RG-012 ... [Published PBR - News - Jul 22 2014]
US-based biopharmaceutical firm Regulus Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for RG-012, a single stranded, chemically modified oligonucleotide. ...
Regulus Receives Orphan Drug Designation for RG... [Published PR Newswire: Policy & Public Interest - Jul 21 2014]
LA JOLLA, Calif., July 21, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the U.S. Food & Drug Administration ...
Regulus Announces Patent Grant from U.S. Patent... [Published PR Newswire: Policy & Public Interest - Jun 25 2014]
LA JOLLA, Calif., June 25, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that the U.S. Patent and Trademark ...
Watching "Knots Landing" on Arcturus [Published Boing Boing - May 28 2014]
This handy chart shows you how far our TV shows have traveled through space . The first televised baseball game is about to hit Regulus. ...
Regulus and Southern Legacy Announce Agreement ... [Published Marketwire - Breaking News Releases - May 20 2014]
CALGARY, ALBERTA--(Marketwired - May 20, 2014) - Regulus Resources Inc. ("Regulus") (TSX VENTURE:REG) and Southern Legacy Minerals Inc . ("Southern Legacy") (TSX VENTURE:LCY) are pleased to announce the signing of a binding agreement dated May ...
1 2 3 4 5 6 7

Press Releases

sort by: Date | Relevance
Regulus Renews Strategic Alliance with Sanofi t... [Published Financial Services - Feb 05 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.